Crossmark

Post-COVID-19 lung disease: utility of biochemical and imaging markers in uncovering residual lung inflammation and monitoring anti-inflammatory therapy, a prospective study

Crossref DOI link: https://doi.org/10.1007/s00259-025-07297-w

Published Online: 2025-05-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khandelwal, Yogita

Ora, Manish

Jain, Bela

Dixit, Manish

Singh, Prakash

Khan, Ajmal

Nath, Alok

Agarwal, Vikas

Gambhir, Sanjay https://orcid.org/0000-0001-8764-3890
License Information

Text and Data Mining valid from 2025-05-13

Version of Record valid from 2025-05-13
More Information

Article History

Received: 24 January 2025

Accepted: 21 April 2025

First Online: 13 May 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of SGPGI, Lucknow India (IEC code: 2021-6-MD-118 dated 14.07.21).

: Informed consent was obtained from all individual participants included in the study.

: The authors affirm that human research participants provided informed consent for publication of the images.

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below